Overview

3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma

Status:
Completed
Trial end date:
2008-09-22
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as 3-AP, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 3-AP in treating patients who have locally recurrent or metastatic renal cell (kidney) carcinoma (cancer).
Phase:
Phase 2
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborator:
National Cancer Institute (NCI)